Strong Growth in Innovative Drug Revenue, Biopharmaceutical Companies' Performance Shows High "Innovation" Content

Benefiting from improved industry sentiment, continuous expansion in overseas markets, and the gradual implementation of favorable pharmaceutical policies, A-share biopharmaceutical companies have moved from a long-term phase of "cash-burning R&D" to a new stage of "profit realization" in 2025. As of March 29, over 70 biopharmaceutical companies have released their 2025 performance data. Among them, 61 companies achieved profitability, accounting for nearly 90%; 29 companies saw year-on-year positive growth in net profit attributable to the parent company (excluding those turning losses into profits), with 7 companies doubling their performance. In addition, companies such as RemeGen, InnoCare Pharma, and Digital Human are expected to turn losses into profits, while companies like MicuRx, Junshi Biosciences, and Mabwell have achieved year-on-year reduced losses. (Shanghai Securities News)